Nasdaq Futures Rise, PetMed Express Stock Soars 32%
Stock futures are higher before the open, with the Nasdaq leading gains as investors move back toward growth and technology names after last week's pressure. Oil prices are also easing from recent highs, reducing fears that a geopolitical shock could spill into inflation expectations.The key theme this week is shifting from geopolitics back toward macro data. Investors are watching labor market releases, including JOLTS and Thursday's payroll report, for clues on the Federal Reserve path. Markets continue to weigh a resilient economy against concerns that sticky inflation could keep the Fed more restrictive than expected.In pre-market trading, S&P 500 futures rose 0.76%, Nasdaq futures rose 1.03% and Dow futures rose 0.41%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -PetMed Expressup 32% after SilverCape Investments released an open letter to its board of directors calling on the board to engage with SilverCape on a revised proposal to acquire all outstanding shares of common stock of PetMed for $3.00 per share in cash with no financing contingencyCharterand SpaceXand up 24% and 2%, respectively, after a report that the companies discussed partnering on a consumer mobile phone offeringComcastup 21% after announcing its intention to separate into two independent publicly traded companies through a tax-free spin-off of NBCUniversal and SkyIridiumand Rocket Labup 22% and 9%, respectively, after Rocket Lab agreed to acquire all the outstanding shares of Iridium common stock for $54 per share in a cash and stock transactionLOWER -Zymeworksand Theravance Biopharmaboth down 2% after Zymeworks entered into a definitive agreement to acquire Theravance Biopharma for $17.00 per shareMartin Mariettadown 2% after entering into a definitive agreement to combine with Lhoist North America, a subsidiary of Lhoist Group, for $13.5B in cash and shares of Martin Marietta common stockBritish American Tobaccodown 1% after reporting its Fit2Win cost-cutting initiatives will impact 9,000 jobsVerizondown 1% after BT Groupand the company announced the signing of an agreement to combine their respective international enterprise operations into a 50:50 joint venture
Trade with 70% Backtested Accuracy
Analyst Views on PETS
About PETS
About the author

- Acquisition Proposal Confirmation: PetMed Express's Board confirmed receipt of an unsolicited proposal from SilverCape Investments to acquire all outstanding shares at $3.00 per share in cash, following a previous offer of $4.00 per share in December 2025, indicating ongoing interest from the acquirer.
- Board Evaluation Process: The Board, with the assistance of financial and legal advisors, will carefully evaluate the proposal to determine the best course of action for the Company and all shareholders, demonstrating the company's commitment to shareholder value.
- Diligence Materials Prepared: Although the Company prepared extensive diligence materials and a formal management presentation for SilverCape, the acquirer ultimately declined to sign a nondisclosure agreement with a standard standstill provision, reflecting the complexities involved in the acquisition negotiations.
- Uncertainty of Future Transactions: The Board has not reached any determination regarding SilverCape's latest proposal and cannot assure that any transaction will result, indicating the Company's cautious approach in acquisition discussions while remaining focused on core operations and maximizing long-term shareholder value.
- Revised Acquisition Proposal: Singapore-based SilverCape Investments has proposed to acquire all outstanding shares of PetMed Express for $3.00 per share in cash, reflecting the company's ongoing deterioration and aiming to provide shareholders with a superior alternative to the current value-destructive trajectory.
- Value Warning: In an open letter, SilverCape warned that PetMed is no longer viable as a public company due to dismal quarterly and fiscal reports, rapidly depleting cash reserves, and ineffective leadership, urging the Board to act swiftly to prevent further erosion of the company's remaining value.
- Positive Market Reaction: In pre-market trading, PetMed's stock rose by 32.43% to $2.3399, indicating a positive market response to SilverCape's acquisition proposal, although the current price remains below the proposed offer.
- Support for Independent Evaluation: SilverCape expressed openness to other third-party alternatives that offer superior value and supports PetMed in conducting a structured and independent process to consider these alternatives, demonstrating a commitment to the company's future and shareholder interests.
- Market Indicator Surge: The NASDAQ 100 Pre-Market Indicator increased by 244.55 points to 29,362.79, indicating a positive shift in market sentiment that may attract more investor interest in tech stocks.
- Active Stock Performance: NN, Inc. (NNBR) rose by $1.31 to $4.07 with a trading volume of 39,045,126 shares, currently at 67.83% of its target price, reflecting market confidence in its future performance.
- Other Stock Movements: Comcast Corporation (CMCSA) increased by $5.38 to $28.55 with 7,275,313 shares traded, currently at 89.22% of its target price, suggesting optimistic expectations from investors regarding its growth potential.
- Bitcoin ETF Performance: iShares Bitcoin Trust ETF (IBIT) gained $0.35 to $34.20, representing a 4.14% increase from its 52-week low, highlighting ongoing market interest and investment enthusiasm in cryptocurrencies.
- Proposal Revision: SilverCape Investments announced on Monday that it has revised its proposal to acquire all outstanding shares of PetMed Express (PETS), lowering its cash offer from $4 per share made in December 2025 to $3 per share, reflecting the company's deteriorating financial condition.
- Shareholder Premium: Despite the reduced offer, SilverCape claims the new proposal still represents a roughly 70% premium over PetMed's closing price of $1.76 on June 26, aiming to provide shareholders with immediate liquidity amid current financial challenges.
- Deteriorating Business: SilverCape highlighted that PetMed's business has continued to weaken since the original proposal, citing declining prescription medication revenue, falling repeat customer sales, rising customer acquisition costs, negative adjusted EBITDA, and a drop in cash from $54.7 million to $21.4 million over the past fiscal year.
- Governance Concerns: SilverCape raised concerns about PetMed's leadership and governance, noting high executive turnover, low insider ownership, and the board's handling of previous acquisition proposals, urging the board to engage with its proposal or conduct a bona fide sale process.
- Destruction of Shareholder Value: SilverCape Investments highlights that PetMed's stock plummeted from $32.30 on July 2, 2021, to $1.76 on June 26, 2026, indicating severe governance failures and a lack of strategic direction that has eroded shareholder value.
- Acquisition Proposal: SilverCape proposes to acquire PetMed for $3.00 per share in cash, representing a 70% premium over the current stock price, aiming to provide immediate liquidity to shareholders and prevent further erosion of the company's value.
- Leadership Instability: PetMed has seen two CEOs and CFOs depart in the past two years, with current Chair and Interim CEO Leslie C.G. Campbell's leadership being questioned, resulting in a lack of effective strategic direction for the company.
- Governance Failures: The board members own only 2% of the company’s shares, showing a lack of accountability to shareholders, and the company has failed to file financial reports on time, exacerbating shareholder concerns about its future.
- Destruction of Shareholder Value: SilverCape Investments highlights that PetMed's stock price plummeted from $32.30 on July 2, 2021, to $1.76 on June 26, 2026, indicating severe mismanagement and strategic failures that have led to significant shareholder value erosion.
- Acquisition Proposal: SilverCape has proposed to acquire all outstanding shares of PetMed for $3.00 per share in cash, representing approximately a 70% premium over the current stock price, aimed at providing immediate liquidity to shareholders and preventing further value loss.
- Leadership Instability: PetMed has seen the departure of two CEOs and CFOs in just two years, with Chair and Interim CEO Leslie C.G. Campbell receiving a $1.3 million salary, which starkly contrasts with the company's sub-$40 million market capitalization, severely undermining investor confidence.
- Governance Failures: The board members own only 2% of PetMed's shares, demonstrating a lack of accountability to shareholders, while ineffective governance structures leave shareholders with almost no means to hold directors accountable, exacerbating the ongoing decline in company value.









